An Open-Label, Multicenter, Phase I/II Study of AT-101 in Combination With Docetaxel and Prednisone in Men With Hormone Refractory Prostate Cancer (HRPC).
Latest Information Update: 10 Nov 2021
At a glance
- Drugs AT 101 (Primary) ; Docetaxel; Prednisone
- Indications Prostate cancer
- Focus Therapeutic Use
- 23 Nov 2011 Results published in the Annals of Oncology.
- 09 Feb 2010 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
- 09 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.